Eleanor Garth

2 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp Earlier this week, the XPRIZE Foundation announced the 40 semi-finalist teams in its $101 million Healthspan competition – a global initiative designed to catalyze scalable interventions that restore muscle, cognitive and immune function by at least a decade in adults aged 50 to 80.

3 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp After a year of fiscal contraction and economic caution, the longevity sector has staged a return to form – albeit not in the manner some might have expected. Rather than chasing exuberant deal volumes or early-stage gambles, investors in 2024 favored focus over fervor; capital flowed into companies positioned to advance beyond proof-of-concept, with discovery platforms and later-stage VC dominating the field.

4 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp The race to improve how long we live well has entered a new phase. XPRIZE Healthspan, the seven-year, $101 million global competition announced in late 2023, has unveiled its first cohort of semifinalists – 100 teams from 58 countries tasked with developing therapies to extend the years we spend in good health.

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp In what may be a defining test for national-scale artificial intelligence in healthcare, the United Kingdom has trained a generative AI model on the medical histories of nearly its entire population. The model – named Foresight – was developed using deidentified NHS data from 57 million patients and is designed to predict more than a thousand future disease diagnoses, including hospital admissions, complications and major events such as myocardial infarction.

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp Osteoboost Health has announced the national availability of its newly FDA-cleared wearable device designed to treat low bone density – specifically osteopenia, a stage of bone thinning that precedes osteoporosis but which accounts for more than half of all fragility fractures. Osteoboost is the first prescription-only medical device of its kind cleared by the FDA to treat low bone density.